The intrathecal administration of the SOD1-targeting ASO Tofersen has yielded promising results in phase-3 clinical studies, which have led to the authorization of an ongoing early access program for the use of Tofersen in all individuals with SOD1-ALS (14, 15). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.